AI Terminal
Zur Rose Group AG
Board/Management Information • Mar 4, 2019
1021_rns_2019-03-04_c04cb527-99a2-478a-a5e5-77cb96dffe61.html
Board/Management Information
Open in ViewerOpens in native device viewer
News Details
Corporate | 4 March 2019 07:00
Change on the Board of Directors of the Zur Rose Group
EQS Group-News: Zur Rose Group AG / Key word(s): Personnel
04.03.2019 / 07:00
Press release
Change on the Board of Directors of the Zur Rose Group
Vanessa Frey and Dr. Heinz O. Baumgartner have decided not to stand again for re-election to the Zur Rose Group’s Board of Directors at the next Annual General Meeting. This move is associated with differences of opinion about how and how fast the growth strategy should be implemented.
Both the Board of Directors and Group Management thank Vanessa Frey and Heinz Baumgartner for their dedicated service in the highest governing body of the Zur Rose Group.
The Board of Directors is seeking to strengthen the Board further with tech expertise and commercial experience. It will nominate two suitably qualified candidates for election at the Annual General Meeting to be held on 23 May 2019.
Investors and analyst contact
Marcel Ziwica, Chief Financial Officer
Email: [email protected], phone: +41 58 810 11 49
Media contact
Lisa Lüthi, Head of Corporate Communications
Email: [email protected], phone: +41 52 724 08 14
Financial Calendar
21 March 2019 Annual Results 2018
17 April 2019 Q1/2019 Trading Update
23 May 2019 Annual General Meeting
21 August 2019 2019 Half-Year Results
23 October 2019 Q3/2019 Trading Update
Zur Rose Group
The Swiss Zur Rose Group is Europe’s largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. With its business model, it offers high-quality, safe and cost-effective pharmaceutical care and thus contributes to reducing healthcare costs. It is also characterized by the continuous further development of digital services in the field of drug management and actively promotes its positioning as a comprehensive, integrated cross-service healthcare platform. The creation of added value and a pronounced patient orientation make the Group an important strategic partner for service providers, cost units and industry.
The Zur Rose Group is internationally present with strong brands, including Germany’s best-known pharmacy brand DocMorris. The company employs over 1,000 people at various locations and generated a turnover of CHF 1,207 million in the 2018 financial year. The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). The CHF 115 million corporate bond issued in July 2018 is also listed on the SIX Swiss Exchange (securities number 42146044, ISIN CH0421460442, ticker ZRO18). Further information at zurrosegroup.com
End of Corporate News
| Language: | English |
| Company: | Zur Rose Group AG |
| Walzmühlestrasse 60 | |
| 8500 Frauenfeld | |
| Switzerland | |
| Phone: | +41 52 724 08 14 |
| Internet: | www.zurrosegroup.com |
| ISIN: | CH0042615283 |
| Listed: | SIX Swiss Exchange |
| End of News | EQS Group News Service |